Beckman Coulter Inc

Beckman Coulter — Q4 2009 Earnings Presentation

13 slides from Beckman Coulter's earnings presentation, Feb 11, 2010

  1. Slide 1: Beckman Coulter Q4 2009 Financial Presentation

    1 BEC Q4 2009 Conf Call & Beckman Coulter Q4 2009 – Financial Presentation Scott Garrett Chairman, President & Chief Executive Officer Exhibit 99.2

  2. Slide 2: Key Observations Q4 2009

    Key Observations Q4 2009 Excellent finish to a solid year: #1 Recurring Revenue (ex & cc) : Full year 6.5% #2 Olympus: Revenue acceleration to $120M Accretive to adjusted EPS #3 Expanded Earnings and Cash Flow Adjusted EPS: $1.29 (ex Olympus intangibles amortization) Free Cash Flow YTD: $238M #4 201

  3. Slide 3: Growth in Diagnostics (ex Olympus)

    Growth in Diagnostics (ex Olympus) 6.4% (cc) Immunoassay and Hemostasis grew above market Access Immunoassay 9.5% (cc) Recurring Revenue: Q4 2009 ($ millions) Total Revenue % Chg in constant currency Total Recurring Revenue % Chg in constant currency Consolidated Diagnostics Beckman Coulter Product

  4. Slide 4: Diagnostics and Life Science

    Diagnostics Customer preference for OTLs Life Science Rebound in Europe and Japan Cash Instrument Sales: Q4 2009 ($ millions) (2.3%) Total Cash Instrument Sales % Chg in constant currency Consolidated Diagnostics Beckman Coulter Product Area

  5. Slide 5: Revenue by Geography: Q4 2009

    Revenue by Geography: Q4 2009 ($ millions) (0.3%) United States % Chg International % Chg in constant currency Consolidated Diagnostics Beckman Coulter United States: Recurring revenue up mid-single digits Diagnostics: Robust growth in Hemostasis; weakness in Clinical Automation and Flow Cytometry L

  6. Slide 6: Financial Presentation - Chief Financial Officer

    6 BEC Q4 2009 Conf Call & Beckman Coulter Q4 2009 – Financial Presentation Charlie Slacik SVP & Chief Financial Officer

  7. Slide 7: Adjusted P & L: Q4 2009

    Adjusted P & L: Q4 2009 ($ millions) Pretax income After tax income Amortization of intangible assets* 173.6 Cost of Sales Cost of recurring revenue Cost of cash instrument sales TOTAL $1.29* EPS diluted % Chg 223.2 17.6 205.6 (2.3%) Revenue: Recurring revenue % Chg in constant currency Cash instrum

  8. Slide 8: Adjusted P & L: 2009 Year

    Adjusted P & L: 2009 Year ($ millions) Pretax income After tax income Amortization of intangible assets* $1,223.3 512.5 $1,735.8 Cost of Sales Cost of recurring revenue Cost of cash instrument sales TOTAL $3.90* EPS diluted % Chg $2,645.2 615.4 (11.3%) $3,260.6 26.8 $2,486.7 588.6 (15.0%) $3,075.3 R

  9. Slide 9: 2009 Outlook vs Actuals (Adjusted)

    2009 Outlook vs Actuals (Adjusted) 2009 Outlook 2009 Actuals Total revenue: Reported * Constant Currency * Flat 0% to 2% (0.8%) Recurring rev. (cc) * 6% to 7% Op income margin ** ~ 13% Tax rate ~ 25% EPS: Consolidated ** $3.77 to $3.87 * Excludes Olympus ** Excludes Olympus intangibles amortization

  10. Slide 10: Balance Sheet & Cash Flow

    Balance Sheet & Cash Flow Full Year 2009 CAPEX: $30M Increase in PP&E CAPEX offset by lower OTL CAPEX DSO: 3 day improvement Inventory turns (ex Olympus): 3.4 to 3.2 (cc) Adjusted EBITDA TTM: $739M 19% Operating cash flow: $560M Free cash flow: $238M

  11. Slide 11: Olympus Integration

    Olympus Integration Progress to Date 2010 Anticipated synergies: $50 to $60 million Commercial integration complete Olympus Immunoassay closure Rationalized Chemistry systems development Processing business on Olympus systems / moving to Oracle Anticipated synergies offset by revenue impact: OTL tra

  12. Slide 12: 2010 Outlook

    2010 Outlook* Total revenue $3.8 B to $3.9 B $480 M - $500 M BEC recurring revenue 6% to 8% Op Margin ~ Non-Op expense $88 M Tax rate 26% to 27% Share count 71.3 M Adjusted EPS ** $4.40 to $4.55 CAPEX $375 M Depreciation & Amortization $350M to $375 M * 2010 outlook is based on currency exchange rat

  13. Slide 13: Forward-Looking Statements and Non-GAAP Financial Information

    Forward-Looking Statements and Non-GAAP Financial Information This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements expectat

Beckman Coulter — Q4 2009 Earnings Presentation on 6ix